Radioactive pill tested in healthy men to map huntington Drug's path
NCT ID NCT07516899
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study will give 8 healthy men a single radioactive dose of LPM3770164, a drug being developed for Huntington disease. Researchers will measure how much of the drug is recovered in urine and stool, and identify its breakdown products. The goal is to understand how the drug is processed and eliminated, not to treat the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LPM3770164 (a radioactive drug)
What this could lead to
If successful, this study will show how the drug moves through and leaves the body, which is a necessary step before testing it as a treatment for Huntington disease.
What could go wrong
This is a very early, small study in just 8 healthy men, not people with Huntington disease. It is designed only to measure drug processing, not to treat or improve symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••